untitled
|
|
- さや いのら
- 7 years ago
- Views:
Transcription
1
2
3 1
4 2
5 3
6 4
7 5
8 6
9 7
10 8
11 9
12 10
13 11
14 12
15 13
16 14
17 15
18 16
19 17
20 18
21 19
22 20
23 21
24 22
25 23
26 1 24
27 25
28 26
29 27
30 1 28
31 k k k 29
32 30
33 31
34 32
35 33
36 () 34
37 35
38 36
39 () 37
40 () () () 38
41 39
42 40
43 41
44 42
45 43
46 2 2 44
47 45
48 46
49 47
50 48
51 49
52 50
53 51
54 52
55 53
56 54
57 55
58 56
59 57
60 58
61 59
62 () () () 60
63 μμ μ 61
64 II 62
65 63
66 64
67 65
68 66
69 (4)(5) 67
70 68
71 69
72 70
73 71
74 72
75 73
76 74
77 75
78 76
79 77
80 78
81 79
82 80
83 81
84 82
85 83
86 84
87 85
88 1 3 86
89 87
90 2 88
91 89
92 90
93 91
94 92
95 93
96 AAFFBHPBC14UND 100ME technical 94
97 GelvatolMonsanto Dow Corning Malathion Malathion Gelvatol Antiform Malathion Papi Upjohn 95
98 Kelzun cadusafos SS-di-sec-bytyl O-ethylphospho rodithioate C10H23O2PS2 96
99 97
100 98
101 99
102 100
103 101
104 102
105 103
106 14 α 2 104
107 D.Law et al.j.antimicrob.chemother
108 E.Martin et al.antimicr.agents and Chemother Abstr.Ann.Meeting Am.Soc.Microbiol Candida albicans Eur.J.Clin.Microbiol.Infect.Dis in vitro Drugs Today :1 1:500 25:1 1:125 Candida albicanscandida TorulopsisglabrataCandida krusei Candida tropicalis Cryptococcus neoformans Cryptococcus Trichophyton metagrophytes Trichophyton Candida albicans
109 in vitro g/ml g/ml TerbFlu ItraC. 107
110 108
111 109
112 .. α α 110
113 111
114 112
115 113
116 114
117 115
118 116
119 117
120 (a) (b) (a) (a) (b) (c) (d) (e) (e) (e) (f) (b) (g) (e) (f) (g) 118
121 (b) 119
122 120
123 121
124 122
125 123
126 [] [] 124
127 125
128 126
129 127
130 128
131 129
132 130
133 131
134 132
135 133
136 134
137 135
138 136
139 137
140
141 139
142 140
143 141
144 4 142
145 143
146
147 2 145
148 146
149 147
150 6 148
151 2 149
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
More information感染症学雑誌第80巻第6号
Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ
More information日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
More information平成20年5月 協会創立50年の歩み 海の安全と環境保全を目指して 友國八郎 海上保安庁 長官 岩崎貞二 日本船主協会 会長 前川弘幸 JF全国漁業協同組合連合会 代表理事会長 服部郁弘 日本船長協会 会長 森本靖之 日本船舶機関士協会 会長 大内博文 航海訓練所 練習船船長 竹本孝弘 第二管区海上保安本部長 梅田宜弘
More information
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
More information, ,
41 42 73 121 121 10 122 11 122 12 131 13 131 15 10 133 16 11 133 17 12 136 18 13 141 19 14 141 20 15 146 21 16 149 22 17 149 23 174 18 24 73 19 241,301 25 20 242,301 (1) 26 21 331 27 22 241,341 28 23 242,341
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More informationuntitled
i ii (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3) (2) (3) (1) (2) (3) (1) (1) (1) (1) (2) (1) (3) (1) (2) (1) (3) (1) (1) (1) (2) (1) (3) (1) (1) (2) (1) (3)
More information平成18年度「商品先物取引に関する実態調査」報告書
... 1.... 5-1.... 6-2.... 9-3.... 10-4.... 12-5.... 13-6.... 15-7.... 16-8.... 17-9.... 20-10.... 22-11.... 24-12.... 27-13... 29-14.... 32-15... 37-16.... 39-17.... 41-18... 43-19... 45.... 49-1... 50-2...
More information1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 ( ) 24 25 26 27 28 29 30 ( ) ( ) ( ) 31 32 ( ) ( ) 33 34 35 36 37 38 39 40 41 42 43 44 ) i ii i ii 45 46 47 2 48 49 50 51 52 53 54 55 56 57 58
More information23 15961615 1659 1657 14 1701 1711 1715 11 15 22 15 35 18 22 35 23 17 17 106 1.25 21 27 12 17 420,845 23 32 58.7 32 17 11.4 71.3 17.3 32 13.3 66.4 20.3 17 10,657 k 23 20 12 17 23 17 490,708 420,845 23
More information日本糖尿病学会誌第58巻第3号
l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More information小動物の皮膚真菌症
Small Animal Dermatomycosis 日 本 大 学 生 物 資 源 科 学 部 獣 医 学 科 獣 医 臨 床 病 理 学 研 究 室 准 教 授 加 納 塁 Rui Kano, Veterinary Pathobiology. (Associate Professor) Nihon University College of Bioresouce Sciences 1. はじめに
More informationVOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
More informationAcecide_ProductsInformation2010PDF.indd
53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =
More informationCandida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
More information- 1 -
- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus
More informationnsg02-13/ky045059301600033210
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More information読めば必ずわかる 分散分析の基礎 第2版
2 2003 12 5 ( ) ( ) 2 I 3 1 3 2 2? 6 3 11 4? 12 II 14 5 15 6 16 7 17 8 19 9 21 10 22 11 F 25 12 : 1 26 3 I 1 17 11 x 1, x 2,, x n x( ) x = 1 n n i=1 x i 12 (SD ) x 1, x 2,, x n s 2 s 2 = 1 n n (x i x)
More information1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
More information第86回日本感染症学会総会学術集会後抄録(I)
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
More information日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
More informationIF_SUPRECUR_N29
! @ # $ % ^ & * ( ) _ + )# ! a s d a s d f g h a s d @ a s d a s # a s d f g h j $ a s d f g h a s d % a s a a s a s a s d f g ^ a s a s a s & a s d f a s d f g h a s d f g a s d f g a s d a s d * s
More information日本化学療法学会雑誌第56巻第3号
β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
More information...1 (1)... 1 (2) ) )... 1 (3)... 1 (4) ) )... 2 (5)... 3 (6)... 3 (7) ) )... 4 (8)... 4 (9)... 4 (10) (1
...1 (1)... 1 (2)... 1 1)... 1 2)... 1 (3)... 1 (4)... 1 1)... 1 2)... 2 (5)... 3 (6)... 3 (7)... 4 1)... 4 2)... 4 (8)... 4 (9)... 4 (10)... 4...5 (1)... 5 1)... 5 2)... 5 (2)... 5 1)... 5 2)... 5 3)...
More informationKRAS KRAS
KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS : KRAS in vitro KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS KRAS
More information1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
More information- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
More information2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
More information20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
More informationI? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
More informationKey words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
More information10 10 10 1 2 3 4 2 2 4 5 6 7 8 1 9 1011 S 10 1 2 3 4 5 10 10 10 1 2 3 4 5 6 2 7 8 9 10 10 2 14 3 2 4 10 11 12 13 14 1521 15 16 15 16 ( ) 17 18 19 20 21 1 10 4 1 2 5 3 2 II 2 3 ( ) 5 21 5 22 2 3 23
More informationN cos s s cos ψ e e e e 3 3 e e 3 e 3 e
3 3 5 5 5 3 3 7 5 33 5 33 9 5 8 > e > f U f U u u > u ue u e u ue u ue u e u e u u e u u e u N cos s s cos ψ e e e e 3 3 e e 3 e 3 e 3 > A A > A E A f A A f A [ ] f A A e > > A e[ ] > f A E A < < f ; >
More information菌種 報告年 株数 MIC(μg/mL) Range MIC50 MIC > ( 幾何平均 ) C.tropicalis >
生物学的同等性試験におけるイトリゾール カプセル 50 のロット間での統計学 的有意差が本剤の有効性及び安全性に与える影響について イトリゾール カプセル 50 は,1993 年に内臓真菌症 ( 深在性真菌症 ), 深在性皮膚真菌症及び表在性皮膚真菌症を適応症として承認され, その後,1999 年に爪白癬等の適応を追加,2004 年及び 2006 年にはそれぞれ爪白癬のパルス療法および注射剤からの切り替えとしての新用法
More information051
Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
More informationt χ 2 F Q t χ 2 F 1 2 µ, σ 2 N(µ, σ 2 ) f(x µ, σ 2 ) = 1 ( exp (x ) µ)2 2πσ 2 2σ 2 0, N(0, 1) (100 α) z(α) t χ 2 *1 2.1 t (i)x N(µ, σ 2 ) x µ σ N(0, 1
t χ F Q t χ F µ, σ N(µ, σ ) f(x µ, σ ) = ( exp (x ) µ) πσ σ 0, N(0, ) (00 α) z(α) t χ *. t (i)x N(µ, σ ) x µ σ N(0, ) (ii)x,, x N(µ, σ ) x = x+ +x N(µ, σ ) (iii) (i),(ii) z = x µ N(0, ) σ N(0, ) ( 9 97.
More informationII III II 1 III ( ) [2] [3] [1] 1 1:
2015 4 16 1. II III II 1 III () [2] [3] 2013 11 18 [1] 1 1: [5] [6] () [7] [1] [1] 1998 4 2008 8 2014 8 6 [1] [1] 2 3 4 5 2. 2.1. t Dt L DF t A t (2.1) A t = Dt L + Dt F (2.1) 3 2 1 2008 9 2008 8 2008
More informationknsp-09/ky082844139000005942
1 4 17 10 : 50 11 : 50 2 4 17 15 : 00 16 : 00 1 4 17 16 : 00 17 : 00 2 4 18 10 : 50 11 : 50 1 4 17 8:50 9:20 2 4 17 9:20 9:50 3 4 17 9:50 10 : 20 4 4 17 10 : 20 10 : 50 5 4 17 10 : 50 11 : 20 6 4 17 11
More information1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET i BALF ii CVF i ii BALF i ii iii BALF i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4)
1. 1) (1) in vitro i ii in vitro ex vivo (2) (3) ET ibalf ii CVF i iibalf i ii iiibalf i ii ET 2) (1) in vitro (2) in vitro (3) in vitro (4) ET CVF (5) (6) 3) (1)in vitro 2. 1)ONO-5046Na (1) (2) (3) (4)
More informationA A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
More information